TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Core Viewpoint - TG Therapeutics, Inc. will hold a conference call on August 6, 2024, to discuss its second quarter financial results and provide a business outlook for 2024 [1][2][3] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, with a research pipeline of investigational medicines [4] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis, and it has also received approvals from the European Commission and the Medicines and Healthcare Products Regulatory Agency for the same treatment in Europe and the UK [4]